Earnings watch

Genentech (DNA) added $2.35 to $48 on 2.5 million shares on Monday after announcing post-market Thursday that it met the Street's first quarter EPS estimate of $0.17, driven by sales of its oncology products, including Rituxan rituximab for non-Hodgkin's lymphoma (see BioCentury Extra, Thursday April 12). Rituxan co-marketer Idec (IDPH) did not trade up on DNA's news. IDPH fell $0.45 to $48.78 on 3.7 million shares on Monday despite announcing that, based on Rituxan sales, it expects to report first quarter EPS of $0.12, $0.02 above the Street's consensus. IDPH expects to report its first quarter results post-market on Thursday. ...